RenovoRx Gets FDA Orphan Drug Designation for Pancreatic Cancer
RenovoRx Achieves Key Milestone in Pancreatic Cancer Treatment
RenovoRx Inc. (NASDAQ: RNXT) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for oxaliplatin in the treatment of pancreatic cancer. This designation provides seven years of market exclusivity upon FDA approval.
TIGER-PaC Trial Enrollment Continues
The company's TIGER-PaC clinical trial is enrolling patients until June 2026, with final data readout expected between mid and late 2027. The trial evaluates RenovoRx's innovative treatment approach for pancreatic cancer.
Orphan Drug Designation is granted to drugs targeting rare diseases, offering benefits such as tax credits and fee waivers. This milestone underscores RenovoRx's commitment to addressing unmet medical needs in pancreatic cancer.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.